PVCT Insider Lacey John III Buys 48,917 Shares
Insider Lacey John III bought shares of Provectus Biopharmaceuticals, joining other executives in recent buying activity.
Reviewed by automated data checks against the source filing. How we make and check alerts
Lacey John III bought 48,917 shares of Provectus Biopharmaceuticals, Inc. ($PVCT) on June 30, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $PVCT is up 0.0% after 1 week, down 14.3% after 1 month and down 28.6% to date (from the $0.07 close on Jun 30, 2026).
PVCT
Provectus Biopharmaceuticals, Inc.
Key Points
- On June 30, 2026, Lacey John III purchased 48,917 shares of Provectus Biopharmaceuticals (OTC: PVCT) at a spot price of $0.07, but the transaction value was not disclosed.
- This acquisition adds to a series of insider buys on the same day, with Webster Bailey and Dominic Rodrigues also increasing their stakes.
- Provectus Biopharmaceuticals focuses on developing innovative therapies for conditions like melanoma and other serious diseases, with a market cap of about $23.5 million.
Get $PVCT trade alerts by text
We text you when insiders, Congress or big funds trade $PVCT. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Provectus Biopharmaceuticals, Inc. alert may contain errors. Disclosures
Lacey John III Joins Insider Buying Trend
On June 30, 2026, Lacey John III bought 48,917 shares of Provectus Biopharmaceuticals, Inc. (OTC: PVCT) at a spot price of $0.07. The transaction value wasn't disclosed, but it reflects active insider buying at the company.
Other Insiders Buying Shares
Lacey John III's purchase is part of a growing trend among Provectus insiders. On the same day, Webster Bailey also acquired 48,917 shares, and Dominic Rodrigues, the company's president, purchased 45,860 shares. This collective buying activity suggests increased confidence among company leaders in the future prospects of Provectus.
How Provectus Biopharmaceuticals, Inc. Stock Has Traded
Provectus Biopharmaceuticals' shares are currently trading at around $0.07, which is near its 52-week high of $0.09 but above the low of $0.04. The stock has experienced some fluctuations, but the recent insider activity might influence market sentiment positively.
What Provectus Biopharmaceuticals, Inc. Does
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology firm based in Knoxville, TN. It specializes in developing immunotherapy treatments for diseases such as melanoma, liver cancer, and skin conditions. The company is working on various treatments, including its lead molecule, rose bengal sodium, which is designed for multiple serious health issues.
What's Ahead for Provectus Biopharmaceuticals, Inc.
Provectus is set to report its next earnings on August 11, 2025. As the company continues its developments, the recent insider buying may provide signals about management's confidence in the company's future direction. These transactions, reported under the SEC's guidelines, offer insights into the executives' perspectives on their own company.
Related Filing Alerts
Source: Lacey John III's Form 4 filing on $PVCT (Jun 30, 2026). Find the original filing: PVCT Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts